The cardiovascular polypill: Clinical data and ongoing studies

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages S8-S14

  Castellano, José M ^a,b,c   Bueno, Héctor ^a,d,e   Fuster, Valentín ^a,c  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b Grupo HM Hospitales   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cardiovascular polypill; Primary prevention; Secondary prevention; Treatment adherence

Indexed keywords

CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; ROSUVASTATIN; CARDIOVASCULAR AGENT; DRUG COMBINATION;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; MEDICATION COMPLIANCE; PILL; POLYPILL; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SECONDARY PREVENTION; SOCIAL STATUS; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; PROCEDURES; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DRUG COMBINATIONS; HUMANS; MEDICATION ADHERENCE; SECONDARY PREVENTION;

EID: 84964901244     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/S0167-5273(15)31027-5     Document Type: Article

References (45)

1. Organization WH. Global status report on noncommunicable diseases 2010. Geneva, 2011. 2012.
2. D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman et al. Executive Summary: Heart Disease and Stroke Statistics - 2015 Update A Report From the American Heart Association Circulation 131 4 2015 434 441
3. V Fuster, BM Mearns The CVD paradox: mortality vs prevalence Nat Rev Cardiol 6 11 2009 669
4. M Nichols, N Townsend, P Scarborough, M Rayner Cardiovascular disease in Europe: epidemiological update Eur Heart J 34 39 2013 3028 3034
5. PA Heidenreich, JG Trogdon, OA Khavjou, J Butler, K Dracup, MD Ezekowitz et al. Forecasting the future of cardiovascular disease in the United States a policy statement from the American heart association Circulation 123 8 2011 933 944
6. AS Daar, PA Singer, DL Persad, SK Pramming, DR Matthews, R Beaglehole et al. Grand challenges in chronic non-communicable diseases Nature 450 7169 2007 494 496
7. JM Castellano, R Copeland-Halperin, V Fuster Aiming at strategies for a complex problem of medical nonadherence Global Heart 8 3 2013 263 271
8. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882-7. e1.
9. JM Castellano, G Sanz, JL Peñalvo, S Bansilal, A Fernández-Ortiz, L Alvarez et al. A polypill strategy to improve adherence: results from the FOCUS project J Am Coll Cardiol 64 20 2014 2071 2082
10. AJ Claxton, J Cramer, C Pierce A systematic review of the associations between dose regimens and medication compliance Clin Therapeutics 23 8 2001 1296 1310
11. S Mendis, D Abegunde, S Yusuf, S Ebrahim, G Shaper, H Ghannem et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) Bull World Health Organization 83 11 2005 820 829
12. S Yusuf, S Islam, CK Chow, S Rangarajan, G Dagenais, R Diaz et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 9798 2011 1231 1243
13. World Health Organization. Secondary prevention of noncommunicable disease in low and middle income countries through community-based and health service interventions. (WHO-Wellcome Trust meeting report 1-3.). 2002. Geneva.
14. S Yusuf Two decades of progress in preventing vascular disease Lancet 360 9326 2002 2 3
15. NJ Wald, MR Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 7404 2003 1419
16. JM Castellano, G Sanz, A Fernandez Ortiz, E Garrido, S Bansilal, V Fuster A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality J Am Coll Cardiol 64 6 2014 613 621
17. TIP Study Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 9672 2009 1341 1351
18. S Yusuf, P Pais, A Sigamani, D Xavier, R Afzal, P Gao et al. Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases The Second Indian Polycap Study (TIPS-2) Investigators Circulation: Cardiovascular Quality and Outcomes 5 4 2012 463 471
19. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European journal of preventive cardiology. 2014:2047487314530382.
20. S Thom, N Poulter, J Field, A Patel, D Prabhakaran, A Stanton et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the umpire randomized clinical trial JAMA 310 9 2013 918 929
21. V Selak, CR Elley, C Bullen, S Crengle, A Wadham, N Rafter et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care BMJ 2014 348
22. G Sanz, V Fuster Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population Nat Clin Prac Cardiovasc Med 6 2 2009 101 110
23. LE Bautista, LM Vera-Cala, D Ferrante, VM Herrera, JJ Miranda, R Pichardo et al. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in latin america Health Affairs 32 1 2013 155 164
24. A Shroufi, R Chowdhury, R Anchala, S Stevens, P Blanco, T Han et al. Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review BMC Public Health 13 1 2013 285
25. K Ito, WH Shrank, J Avorn, AR Patrick, TA Brennan, EM Antman et al. Comparative Cost-effectiveness of interventions to improve medication adherence after myocardial infarction Health Serv Res 47 6 2012 2097 2117
26. TA Gaziano, LH Opie, MC Weinstein Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis Lancet 368 9536 2006 679 686
27. V Becerra, A Gracia, K Desai, S Abogunrin, S Brand, R Chapman et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK BMJ Open 5 5 2015
28. D Xavier, P Pais, A Sigamani, J Pogue, R Afzal, S Yusuf et al. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study Nat Clin Prac Cardiovasc Med 6 2 2009 96 97
29. F Malekzadeh, T Marshall, A Pourshams, M Gharravi, A Aslani, A Nateghi et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors Int J Clin Prac 64 9 2010 1220 1227
30. EZ Soliman, S Mendis, WP Dissanayake, NP Somasundaram, PS Gunaratne, IK Jayasingne et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization Trials 12 2011 3
31. PC Group, A Rodgers, A Patel, O Berwanger, M Bots, R Grimm et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PloS One 6 5 2011 e19857
32. M Ezzati, SV Hoorn, A Rodgers, AD Lopez, CD Mathers, CJ Murray et al. Estimates of global and regional potential health gains from reducing multiple major risk factors Lancet 362 9380 2003 271 280
33. KM Narayan, GA Mensah, S Sorensen, YJ Cheng, F Vinicor, MM Engelgau et al. Combination pharmacotherapy for cardiovascular disease prevention: threat or opportunity for public health? Am J Preven Med 29 5 Suppl 1 2005 134 138
34. G Sanz, V Fuster Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population Nat Clin Prac Cardiovasc Med 6 2 2009 101 110
35. S Yusuf, P Pais, A Sigamani, D Xavier, R Afzal, P Gao et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators Circ Cardiovasc Qual Outcomes 5 4 2012 463 471
36. A Patel, A Cass, D Peiris, T Usherwood, A Brown, S Jan et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk Eur J Prev Cardiol 22 7 2015 920 930
37. JM Castellano, G Sanz, JL Penalvo, S Bansilal, A Fernandez-Ortiz, L Alvarez et al. A polypill strategy to improve adherence: results from the FOCUS project J Am Coll Cardiol 64 20 2014 2071 2082
38. Heart Outcomes Prevention Evaluation-3 (HOPE-3), available at http://clinicaltrials.gov/show/NCT00468923
39. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran) avaliable at http://clinicaltrials.gov/ct2/show/NCT01271985
40. HeartOutcomes Prevention and Evaluation 4(HOPE-4). http://www.clinicaltrials.gov/show/NCT01826019
41. AM Peterson, L Takiya, R Finley Meta-analysis of trials of interventions to improve medication adherence Am J Health Sys Pharm 60 7 2003 657 665
42. L Osterberg, T Blaschke Adherence to medication N Engl J Med 353 5 2005 487 497
43. R Chowdhury, H Khan, E Heydon, A Shroufi, S Fahimi, C Moore et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences Eur Heart J 34 38 2013 2940 2948
44. M Viswanathan, CE Golin, CD Jones, M Ashok, SJ Blalock, RC Wines et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review Ann Intern Med 157 11 2012 785 795
45. ME Farkouh, WE Boden, V Bittner, V Muratov, P Hartigan, M Ogdie et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials J the Am Coll Cardiol 61 15 2013 1607 1615